Literature DB >> 17971425

Association of TCF7L2 gene polymorphisms with reduced acute insulin response in Hispanic Americans.

Nicholette D Palmer1, Allison B Lehtinen, Carl D Langefeld, Joel K Campbell, Steven M Haffner, Jill M Norris, Richard N Bergman, Mark O Goodarzi, Jerome I Rotter, Donald W Bowden.   

Abstract

CONTEXT: Genetic variation at the transcription factor 7-like 2 locus has been linked to type 2 diabetes in predominantly European-derived populations. The biological basis of these associations remains to be determined.
OBJECTIVE: The objective of this study was to evaluate previously associated variants for association with measures of glucose homeostasis in Hispanic-Americans and African-Americans and determine the biological mechanism(s) through which these variants exert their effect.
DESIGN: This study was the Insulin Resistance Atherosclerosis Family Study (IRAS-FS).
SETTING: The IRAS-FS is a community-based study of Hispanic-Americans (San Antonio, TX, and San Luis Valley, CO) and African-Americans (Los Angeles, CA). PARTICIPANTS: A total of 1040 Hispanic-American and 500 African-American individuals from the IRAS-FS formed the basis of this study. MAIN OUTCOMES MEASURES(S): The primary glucose homeostasis phenotypes of interest in this study were derived from the frequently sampled iv glucose tolerance test and include insulin sensitivity, acute insulin response, and disposition index.
RESULTS: In Hispanic-Americans, significant evidence of association was observed between single-nucleotide polymorphisms rs7903146 and rs112255372 with reduced insulin secretion as measured by acute insulin response and adjusted for the degree of insulin sensitivity (P = 0.032 and 0.036, respectively). Other quantitative measures, e.g. insulin sensitivity or disposition index, were not associated with the single nucleotide polymorphisms examined. In African-Americans there was no evidence of association observed.
CONCLUSIONS: These results suggest that transcription factor 7-like 2 variants could play a role in the pathogenesis of type 2 diabetes in the Hispanic-American population through a mechanism involving insulin secretion.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17971425      PMCID: PMC2190750          DOI: 10.1210/jc.2007-1225

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  27 in total

Review 1.  Convergence of Wnt, beta-catenin, and cadherin pathways.

Authors:  W James Nelson; Roel Nusse
Journal:  Science       Date:  2004-03-05       Impact factor: 47.728

2.  Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes.

Authors:  Valeriya Lyssenko; Roberto Lupi; Piero Marchetti; Silvia Del Guerra; Marju Orho-Melander; Peter Almgren; Marketa Sjögren; Charlotte Ling; Karl-Fredrik Eriksson; Asa-Linda Lethagen; Rita Mancarella; Göran Berglund; Tiinamaija Tuomi; Peter Nilsson; Stefano Del Prato; Leif Groop
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

3.  PedCheck: a program for identification of genotype incompatibilities in linkage analysis.

Authors:  J R O'Connell; D E Weeks
Journal:  Am J Hum Genet       Date:  1998-07       Impact factor: 11.025

4.  Multipoint quantitative-trait linkage analysis in general pedigrees.

Authors:  L Almasy; J Blangero
Journal:  Am J Hum Genet       Date:  1998-05       Impact factor: 11.025

5.  Genetic epidemiology of insulin resistance and visceral adiposity. The IRAS Family Study design and methods.

Authors:  Leora Henkin; Richard N Bergman; Donald W Bowden; Darrell L Ellsworth; Steven M Haffner; Carl D Langefeld; Braxton D Mitchell; Jill M Norris; Marian Rewers; Mohammed F Saad; Elizabeth Stamm; Lynne E Wagenknecht; Stephen S Rich
Journal:  Ann Epidemiol       Date:  2003-04       Impact factor: 3.797

Review 6.  Assessment of insulin sensitivity in vivo.

Authors:  R N Bergman; D T Finegood; M Ader
Journal:  Endocr Rev       Date:  1985       Impact factor: 19.871

Review 7.  Therapeutic strategies based on glucagon-like peptide 1.

Authors:  Carolyn F Deacon
Journal:  Diabetes       Date:  2004-09       Impact factor: 9.461

8.  Quantitative estimation of insulin sensitivity.

Authors:  R N Bergman; Y Z Ider; C R Bowden; C Cobelli
Journal:  Am J Physiol       Date:  1979-06

9.  Reduced sample number for calculation of insulin sensitivity and glucose effectiveness from the minimal model. Suitability for use in population studies.

Authors:  G M Steil; A Volund; S E Kahn; R N Bergman
Journal:  Diabetes       Date:  1993-02       Impact factor: 9.461

10.  MINMOD: a computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test.

Authors:  G Pacini; R N Bergman
Journal:  Comput Methods Programs Biomed       Date:  1986-10       Impact factor: 5.428

View more
  22 in total

1.  Translating TCF7L2: from gene to function.

Authors:  E R Pearson
Journal:  Diabetologia       Date:  2009-04-22       Impact factor: 10.122

Review 2.  Newly identified loci highlight beta cell dysfunction as a key cause of type 2 diabetes: where are the insulin resistance genes?

Authors:  J C Florez
Journal:  Diabetologia       Date:  2008-05-27       Impact factor: 10.122

3.  The pleiotropic effect of rs7903146 on type 2 diabetes and ischemic stroke: a family-based study in a Chinese population.

Authors:  Jing Song; Yiqun Wu; Juan Juan; Yaying Cao; Tao Wu; Yonghua Hu
Journal:  J Thromb Thrombolysis       Date:  2019-08       Impact factor: 2.300

4.  TCF7L2 genetic variants modulate the effect of dietary fat intake on changes in body composition during a weight-loss intervention.

Authors:  Josiemer Mattei; Qibin Qi; Frank B Hu; Frank M Sacks; Lu Qi
Journal:  Am J Clin Nutr       Date:  2012-10-03       Impact factor: 7.045

5.  Association of 18 confirmed susceptibility loci for type 2 diabetes with indices of insulin release, proinsulin conversion, and insulin sensitivity in 5,327 nondiabetic Finnish men.

Authors:  Alena Stancáková; Teemu Kuulasmaa; Jussi Paananen; Anne U Jackson; Lori L Bonnycastle; Francis S Collins; Michael Boehnke; Johanna Kuusisto; Markku Laakso
Journal:  Diabetes       Date:  2009-06-05       Impact factor: 9.461

6.  Type 2 diabetes gene TCF7L2 polymorphism is not associated with fetal and postnatal growth in two birth cohort studies.

Authors:  Dennis O Mook-Kanamori; Sandra W K de Kort; Cornelia M van Duijn; Andre G Uitterlinden; Albert Hofman; Henriëtte A Moll; Eric A P Steegers; Anita C S Hokken-Koelega; Vincent W V Jaddoe
Journal:  BMC Med Genet       Date:  2009-07-17       Impact factor: 2.103

7.  TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action.

Authors:  Dennis T Villareal; Heather Robertson; Graeme I Bell; Bruce W Patterson; Hung Tran; Burton Wice; Kenneth S Polonsky
Journal:  Diabetes       Date:  2009-11-23       Impact factor: 9.461

8.  Large effects on body mass index and insulin resistance of fat mass and obesity associated gene (FTO) variants in patients with polycystic ovary syndrome (PCOS).

Authors:  Susanne Tan; André Scherag; Onno Eilard Janssen; Susanne Hahn; Harald Lahner; Tiina Dietz; Susann Scherag; Harald Grallert; Carla Ivane Ganz Vogel; Rainer Kimmig; Thomas Illig; Klaus Mann; Johannes Hebebrand; Anke Hinney
Journal:  BMC Med Genet       Date:  2010-01-21       Impact factor: 2.103

9.  Tissue-specific alternative splicing of TCF7L2.

Authors:  Ludmila Prokunina-Olsson; Cullan Welch; Ola Hansson; Neeta Adhikari; Laura J Scott; Nicolle Usher; Maurine Tong; Andrew Sprau; Amy Swift; Lori L Bonnycastle; Michael R Erdos; Zhi He; Richa Saxena; Brennan Harmon; Olga Kotova; Eric P Hoffman; David Altshuler; Leif Groop; Michael Boehnke; Francis S Collins; Jennifer L Hall
Journal:  Hum Mol Genet       Date:  2009-07-14       Impact factor: 6.150

10.  FitSNPs: highly differentially expressed genes are more likely to have variants associated with disease.

Authors:  Rong Chen; Alex A Morgan; Joel Dudley; Tarangini Deshpande; Li Li; Keiichi Kodama; Annie P Chiang; Atul J Butte
Journal:  Genome Biol       Date:  2008-12-05       Impact factor: 13.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.